Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue

Pietro Lapidari, Nardjes Djehal, Julie Havas, Arnauld Gbenou, Elise Martin, Cecile Charles, Sarah Dauchy, Barbara Pistilli, Claire Cadeau, Aurélie Bertaut, Sibille Everhard, Anne Laure Martin, Charles Coutant, Paul Cottu, Gwenn Menvielle, Agnes Dumas, Fabrice Andre, Stefan Michiels, Ines Vaz-Luis, Antonio Di Meglio

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    12 Citations (Scopus)

    Résumé

    Background: Despite the questionable effectiveness of oral complementary and alternative medicine (OCAM) in relieving cancer-related symptoms, including fatigue (CRF), many patients use it aiming to improve their quality of life. We assessed factors associated with OCAM use, focusing on CRF. Methods: Women with stage I–III breast cancer (BC) were included from CANTO (NCT01993498). OCAM use was defined as taking homeopathy, vitamins/minerals, or herbal/dietary supplements. Multivariable multinomial logistic regressions evaluated associations of CRF (EORTC QLQ-C30), patient, and treatment characteristics with OCAM use. Results: Among 5237 women, 23.0% reported OCAM use overall (49.3% at diagnosis, 50.7% starting post-diagnosis), mostly homeopathy (65.4%). Mean (SD) CRF score was 27.6 (24.0) at diagnosis and 35.1 (25.3) at post-diagnosis. More intense CRF was consistently associated with OCAM use at diagnosis and post-diagnosis [adjusted odds ratio (aOR) for 10-point increase 1.05 (95% Confidence interval 1.01–1.09) and 1.04 (1.01–1.09) vs. never use, respectively]. Odds of using OCAM at diagnosis were higher among older [for 5-year increase, 1.09 (1.04–1.14)] and more educated patients [college vs. primary 1.80 (1.27–2.55)]. Women with income > 3000 [vs. < 1500 euros/month, 1.44 (1.02–2.03)], anxiety [vs. not, 1.25 (1.01–1.54)], and those receiving chemotherapy [vs. not, 1.32 (1.04–1.68)] had higher odds of using OCAM post-diagnosis. Conclusion: One-in-four patients reported use of OCAM. More severe CRF was consistently associated with its use. Moreover, older, better educated, wealthier, more anxious women, and those receiving chemotherapy seemed more prone to use OCAM. Characterizing profiles of BC patients more frequently resorting to OCAM may help deliver targeted information about its benefits and potential risks.

    langue originaleAnglais
    Pages (de - à)517-529
    Nombre de pages13
    journalBreast Cancer Research and Treatment
    Volume190
    Numéro de publication3
    Les DOIs
    étatPublié - 1 déc. 2021

    Contient cette citation